Home/ Stocks/ VSTM

Verastem, Inc.

VSTM XNAS

$6.74 +0.81 (+13.71%) ▲ 15-min delayed

Open

$6.65

High

$7.10

Low

$6.02

Volume

4.32M

Market Cap

$519.33M

About Verastem, Inc.

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 102 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$18.67M	$-36,591,000	$-0.37
FY 2025	$30.91M	$-209,471,000	$-3.02
Q3 2025	$11.24M	$-98,518,000	$-1.35
Q2 2025	$2.14M	$-25,934,000	$-0.39

Earnings & Analyst Ratings

Next Earnings: Mon, Nov 2, 2026

Calendar →

Related Market News

No specific coverage for VSTM yet. Check out our latest market news or earnings calendar.

Get VSTM Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Verastem, Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.